Netflix and pill: is there a role for volume-delinked subscription-style payments beyond antimicrobials?’

Can the UK ‘Netflix’ Payment Model Boost the Antibacterial Pipeline?

(2023) Colm Leonard et al.   Applied Health Economics and Health Policy

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis

(2022) Christopher JL Murray et al.   LANCET

Improving Access to High-Value, High-Cost Medicines: The Use of Subscription Models to Treat Hepatitis C using Direct Acting Antivirals in the United States

(2022) Samantha G. Auty et al.   JOURNAL OF HEALTH POLITICS POLICY AND LAW

Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?

(2021) Abigail R. Colson et al.   VALUE IN HEALTH

Realising the broader value of vaccines in the UK

(2021) Simon Brassel et al.   Vaccine: X

Universal Medicine Access through Lump-Sum Remuneration — Australia’s Approach to Hepatitis C

(2019) Suerie Moon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gene therapy: evidence, value and affordability in the US health care system

(2018) Grace Hampson et al.   Journal of Comparative Effectiveness Research

Alternative State-Level Financing for Hepatitis C Treatment—The “Netflix Model”

(2018) Mark R. Trusheim et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION